NCT00598312View on ClinicalTrials.gov

Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Prostate Cancer
Interventions
DRUG

Leuprolide Acetate for Injectable Suspension

Sustained release injectable microspheres, 22.5 mg, one injection every 84 days, 3-month product

Trial Locations (1)

44146

Oakwood Laboratories, LLC, Oakwood Village

Sponsors
All Listed Sponsors
lead

Oakwood Laboratories, LLC

INDUSTRY